- Home
- GTBP vs MBRX Comparison
GTBP vs MBRX Comparison
Compare GTBP & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GTBP | MBRX |
|---|---|---|
| Founded | 1965 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7M | 16.1M |
| IPO Year | 2016 | 2016 |
Fundamental Metrics
Financial Performance| Metric | GTBP | MBRX |
|---|---|---|
| Price | $0.38 | $2.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $61.00 |
| AVG Volume (30 Days) | ★ 1.3M | 516.1K |
| Earning Date | 05-15-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.75 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.26 | $0.26 |
| 52 Week High | $2.29 | $7.98 |
Technical Indicators
Market Signals| Indicator | GTBP | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.12 | 39.55 |
| Support Level | $0.29 | $1.99 |
| Resistance Level | $0.46 | $2.64 |
| Average True Range (ATR) | 0.05 | 0.26 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 27.16 | 0.00 |
Price Performance
Historical ComparisonAbout GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.